ライフサイエンスコーパス: macrophage colony-stimulating factor

1 ytokines (monocyte chemotactic protein-1 and macrophage colony-stimulating factor).

2 ANVAC with per injection GM-CSF (granulocyte-macrophage colony-stimulating factor).

3 innate immunity (eg, recombinant granulocyte-macrophage colony-stimulating factor).

4 CXCL8, CCL2, interleukin-6, and granulocyte-macrophage colony stimulating factor.

5 on and produced IL-22, IL-8, and granulocyte macrophage colony stimulating factor.

6 tion, bacterial infection, starvation and by macrophage colony-stimulating factor.

7 tumor necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor.

8 nd (C-C motif) ligand 2, and the granulocyte macrophage colony-stimulating factor.

9 lodronate treatment or genetic deficiency of macrophage colony-stimulating factor.

10 thogenesis and possibly also for granulocyte-macrophage colony-stimulating factor.

11 ic differentiation from the cells induced by macrophage colony-stimulating factor.

12 of inflammatory signals such as granulocyte-macrophage colony-stimulating factor.

13 had autoantibodies only against granulocyte-macrophage colony-stimulating factor.

14 s with binding sites of IL-3 and granulocyte-macrophage colony-stimulating factor.

15 cognition receptors, and produce granulocyte-macrophage colony-stimulating factor.

16 n innate immune responses toward granulocyte-macrophage colony-stimulating factor.

17 IL-10 and enhanced production of granulocyte-macrophage colony-stimulating factor.

18 y controls were differentiated in vitro with macrophage colony-stimulating factor.

19 l other treatments except CTLA-4/granulocyte macrophage colony-stimulating factor.

20 an alveolar-like phenotype with granulocyte-macrophage colony-stimulating factor.

21 further enhancement of IL-10 and granulocyte-macrophage colony-stimulating factor.

22 tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor.

23 acquisition of responsiveness to granulocyte-macrophage colony-stimulating factor.

24 uction of IFN-gamma, IL-17A, and granulocyte-macrophage colony-stimulating factor.

25 ivator of nuclear factor kappa-B ligand, and macrophage colony-stimulating factor.

26 es interleukin (IL)-6, IL-7, and granulocyte macrophage-colony-stimulating factor.

27 ation and is a signaling effector engaged by macrophage colony-stimulating factor 1 (CSF-1) and recep

28 e were given neutralizing antibodies against macrophage colony-stimulating factor 1 (CSF1 or MCSF) or

29 Production of macrophage colony-stimulating factor 1 (CSF1) by BCCs is

30 ABT induced the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1)

31 nfirmed by results of studies inhibiting the macrophage colony-stimulating factor 1 receptor,whereas

32 tion and bone resorption were studied as the macrophage colony-stimulating factor-1-receptor activato

33 ine, acting via the A(2A) receptor, inhibits macrophage colony-stimulating factor-1-receptor activato

34 eeks) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 mug/m(2) subcu

35 g/m(2) per day) on days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mug/m(2) per d

36 CI -12.4, -33.2 [P = 0.004]) for granulocyte-macrophage colony-stimulating factor, -33.4% (95% CI -20

37 zed to receive human recombinant granulocyte-macrophage colony stimulating factor (64 subjects, 250 m

38 inations of IMA901 (4.13 mg) and granulocyte macrophage colony-stimulating factor (75 mug), with one

39 Herein, we show that granulocyte-macrophage colony stimulating factor, a cytokine critica

40 age colony-stimulating factor or granulocyte-macrophage colony-stimulating factor, all of which stimu

41 and cultured in the presence of granulocyte-macrophage colony-stimulating factor and hepatic stellat

42 made foamy macrophages easily in vitro with macrophage colony-stimulating factor and human serum.

43 c red pulp, where they encounter granulocyte macrophage colony-stimulating factor and interleukin-3,

44 cell enrichment, and cultured in granulocyte-macrophage colony-stimulating factor and interleukin-4 t

45 emotactic protein-1, and reduced granulocyte-macrophage colony-stimulating factor and macrophage infl

46 alyzed) had reduced responses to granulocyte-macrophage colony-stimulating factor and markedly decrea

47 d CXCL10; and the growth factors granulocyte-macrophage colony-stimulating factor and platelet-derive

48 The combined presence of macrophage colony-stimulating factor and receptor activa

49 Cultures from TPH(1)(-/-) in the presence of macrophage colony-stimulating factor and receptor activa

50 age accumulation was partly due to increased macrophage colony-stimulating factor and receptor expres

51 ely produce human interleukin-3, granulocyte-macrophage colony-stimulating factor and Steel factor (N

52 ired high langerin and CD1a with granulocyte-macrophage colony-stimulating factor and transforming gr

53 led to a correlative decrease in granulocyte-macrophage colony-stimulating factor and white blood cel

54 nflammatory protein (MIP)-1beta, granulocyte macrophage colony-stimulating factor) and adaptive cytok

55 leukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at

56 perfamily, to antagonize GM-CSF (granulocyte macrophage colony-stimulating factor) and IL-2 (interleu

57 ocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, and C-reactive pro

58 n-gamma-inducible 10-kd protein, granulocyte-macrophage colony-stimulating factor, and CRP.

59 ma, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and granzyme B), a

60 uding growth-regulated oncogene, granulocyte macrophage colony-stimulating factor, and IL-1beta.

61 matory protein 1alpha and 1beta, granulocyte-macrophage colony-stimulating factor, and interferon-gam

62 xpressed human stem cell factor, granulocyte-macrophage colony-stimulating factor, and interleukin-3,

63 ocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and macrophage inf

64 nterleukin-15, interferon-gamma, granulocyte-macrophage colony-stimulating factor, and monocyte chemo

65 -1beta), hematopoietic IL-7, and granulocyte macrophage colony-stimulating factor, and regulatory IL-

66 chemokine C-X-C motif ligand 5, granulocyte-macrophage colony-stimulating factor, and thrombopoietin

67 nterleukin 17, interferon gamma, granulocyte-macrophage colony-stimulating factor, and tumor necrosis

68 progenitors with a high dose of granulocyte-macrophage colony-stimulating factor; and (iii) directed

69 NF)-alpha, interferon-gamma, and granulocyte-macrophage colony-stimulating factor] and nitric oxide p

70 Interferon-gamma and granulocyte-macrophage colony-stimulating factor are requisite facto

71 autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor at the same site.

72 ontuberculous mycobacteria; anti-granulocyte macrophage colony-stimulating factor autoantibodies and

73 d performed B-cell depletion and granulocyte-macrophage colony-stimulating factor blockade.

74 c cells (DCs) when cultured with granulocyte macrophage-colony-stimulating factor but not with other

75 f the chemokines CCL2, CCL5, and granulocyte-macrophage colony-stimulating factor by gastric epitheli

76 IL-12, IL-17, gamma interferon, granulocyte-macrophage colony-stimulating factor) by CD4(+) and CD8(

77 eptidoglycan, dexamethasone, and granulocyte-macrophage colony stimulating factor, by driving apoptos

78 ression of the interleukin 3 and granulocyte/macrophage-colony stimulating factor common beta-chain r

79 ed pSTAT5 after stimulation with granulocyte-macrophage colony-stimulating factor, compared with cell

80 te colony-stimulating factor and granulocyte-macrophage colony-stimulating factor), consistent with a

81 creased the expression levels of granulocyte-macrophage colony-stimulating factor (CSF), granulocyte

82 Genetic or pharmacologic inhibition of macrophage colony-stimulating factor (CSF-1) signaling b

83 We have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) dire

84 Macrophage-colony stimulating factor (CSF-1) signaling t

85 Cytokine analysis showed that the macrophage colony-stimulating factor CSF1 increased by t

86 mbers of liver macrophages are controlled by macrophage colony-stimulating factor (CSF1).

87 on of Il17a, Csf2 (which encodes granulocyte-macrophage colony-stimulating factor), Cxcl1, and Cxcl5,

88 eric mice lacking B cell-derived granulocyte macrophage colony-stimulating factor develop smaller les

89 IFN-gamma enhanced bacterial replication in macrophage colony-stimulating factor-differentiated macr

90 ntiated macrophages more than in granulocyte-macrophage colony-stimulating factor-differentiated macr

91 ctor, granulocyte colony-stimulating factor, macrophage colony-stimulating factor, eotaxin, interfero

92 GVAX vaccination (consisting of granulocyte macrophage colony-stimulating factor-expressing irradiat

93 This study revealed increased granulocyte-macrophage colony-stimulating factor expression levels i

94 virus (SIV) vaccine coexpressing granulocyte-macrophage colony stimulating factor (GM-CSF) prevented

95 Relative deficiency of granulocyte-macrophage colony stimulating factor (GM-CSF) provided a

96 ects treated with Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF) was presen

97 lony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, IL-

98 crosis factor alpha (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF), interleuk

99 ce the pro-inflammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF).

100 At APE onset, sputum granulocyte macrophage colony stimulating factor (GM-CSF, mean 4.8 [

101 Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) i

102 pressing interleukin (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (oAd) and

103 9513 had increased TNF-alpha and Granulocyte-macrophage colony-stimulating factor (GM-CSF) (P </= 0.0

104 (TM) peptide hydrogel containing granulocyte macrophage colony-stimulating factor (GM-CSF) and CpG OD

105 er coculture with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF) and matrix

106 trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) and peptid

107 senting distinct combinations of granulocyte macrophage colony-stimulating factor (GM-CSF) and variou

108 ninfected adults, including anti-granulocyte macrophage colony-stimulating factor (GM-CSF) autoantibo

109 rs of the interleukin-23 (IL-23)-granulocyte macrophage colony-stimulating factor (GM-CSF) axis in co

110 nterferon (IFN-gamma), CCL4, and granulocyte-macrophage colony-stimulating factor (GM-CSF) by CD8(+)

111 d had reduced productions of the granulocyte-macrophage colony-stimulating factor (GM-CSF) by central

112 s due to the local production of granulocyte macrophage colony-stimulating factor (GM-CSF) by MCs tha

113 s such as CCL-3 (MIP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can enhanc

114 l studies have demonstrated that granulocyte macrophage colony-stimulating factor (GM-CSF) can functi

115 hrough injection of WT mice with granulocyte-macrophage colony-stimulating factor (GM-CSF) DNA reduce

116 ontext, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) drive dend

117 Priming with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances e

118 Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improv

119 Growing evidence shows that granulocyte macrophage colony-stimulating factor (GM-CSF) has progre

120 al antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown

121 anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown

122 e identify an essential role for granulocyte/macrophage colony-stimulating factor (GM-CSF) in orchest

123 oduction of the potent chemokine granulocyte macrophage colony-stimulating factor (GM-CSF) in respons

124 duced production of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) in T(H)17

125 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a medic

126 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleio

127 Here we show that granulocyte macrophage colony-stimulating factor (GM-CSF) is a trigg

128 of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is EGFR de

129 PDA, we show that tumor-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) is necessa

130 udies suggest that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF) level in t

131 Adaptive CD4(+) T cells produced granulocyte-macrophage colony-stimulating factor (GM-CSF) on restimu

132 neutralizing antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumor n

133 iDCs by interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) over 7 day

134 Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a ce

135 O, we tested the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) plus block

136 Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced b

137 Here, we show that deficient granulocyte-macrophage colony-stimulating factor (GM-CSF) production

138 s highlight surprising roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) production

139 lar proteinosis (hPAP) caused by granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor a

140 Here, using granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor-b

141 ny-stimulating factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) resembled

142 Although IFN-gamma and granulocyte-macrophage colony-stimulating factor (GM-CSF) restore im

143 is (PAP) syndrome, disruption of granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling

144 ing SAA treatment or blockade of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling

145 nhances respiratory defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling,

146 ols IgM production via autocrine granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling.

147 ouse cardiac fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF) that acts

148 ole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF) to a contr

149 licate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance

150 rine bone marrow (BM) cells with granulocyte-macrophage colony-stimulating factor (GM-CSF) to generat

151 tested the hypotheses that human granulocyte-macrophage colony-stimulating factor (GM-CSF), a clinica

152 talloproteinase (MMP)-9, IL-1Ra, granulocyte-macrophage colony-stimulating factor (GM-CSF), and C-rea

153 lony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and CXCL1

154 city, constitutive activation of granulocyte macrophage colony-stimulating factor (GM-CSF), and enhan

155 tinuous action of both FLT3L and granulocyte macrophage colony-stimulating factor (GM-CSF), explained

156 s and, when treated ex vivo with granulocyte-macrophage colony-stimulating factor (GM-CSF), generated

157 Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly pr

158 uction of the chemokine CCL2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), respectiv

159 en cultured with soluble ligands granulocyte macrophage colony-stimulating factor (GM-CSF), transform

160 w progenitors in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF), we used G

161 ted the safety and efficacy of a granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immu

162 , which were more efficient than granulocyte-macrophage colony-stimulating factor (GM-CSF)-derived DC

163 rior to that of vaccination with granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing

164 ed macrophages (MDMs), including granulocyte macrophage colony-stimulating factor (GM-CSF)-polarized

165 CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting

166 tokines such as IL-2, IL-15, and granulocyte-macrophage colony-stimulating factor (GM-CSF).

167 be dependent on TH cell-derived granulocyte-macrophage colony-stimulating factor (GM-CSF).

168 on of human blood monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF).

169 on of interleukin 12 (IL-12) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

170 caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF).

171 acterized by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

172 t (RORgammat), IL-17, IL-22, and granulocyte macrophage colony-stimulating factor (GM-CSF).

173 d Bim, and this was inhibited by granulocyte-macrophage colony-stimulating factor (GM-CSF).

174 aracteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

175 which is induced by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF).

176 erated from bone marrow cells by granulocyte-macrophage colony-stimulating factor (GM-CSF)/G-CSF in v

177 1alphaP (CCL3L1), and MIP-1beta; granulocyte-macrophage colony-stimulating factor (GM-CSF); lymphotac

178 Granulocyte macrophage colony-stimulating factor (GM-CSF, Csf2) is a

179 Granulocyte-macrophage colony-stimulating factor (GM-CSF/CSF2) is a

180 mal lower abdominal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF; 75 mug) an

181 We hypothesized that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an agonist

182 s] with PSC supernatants or IL-6/granulocyte macrophage colony-stimulating factor (GM-CSF; positive c

183 dicates that specific cytokines, granulocyte macrophage colony-stimulating factors (GM-CSFs), and ste

184 atopoiesis was also evident, and granulocyte macrophage-colony stimulating factor (GM-CSF) blockade r

185 Here we report that human granulocyte macrophage-colony stimulating factor (GM-CSF) can sensit

186 The pleiotropic cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) enhances a

187 To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling

188 onal myeloid progenitor cells to granulocyte macrophage-colony stimulating factor (GM-CSF) via a larg

189 colitis depends on production of granulocyte macrophage-colony stimulating factor (GM-CSF), which rec

190 es interleukin (IL)-3, IL-5, and granulocyte macrophage-colony-stimulating factor (GM-CSF) and can re

191 ndothelial growth factor but not granulocyte macrophage-colony-stimulating factor (GM-CSF) and induce

192 trating that mutant Shp2 induces granulocyte macrophage-colony-stimulating factor (GM-CSF) hypersensi

193 n-of-function (GOF) Shp2-induced granulocyte macrophage-colony-stimulating factor (GM-CSF) hypersensi

194 Granulocyte-macrophage-colony-stimulating factor (GM-CSF) hypersensi

195 ypersensitivity of JMML cells to granulocyte macrophage-colony-stimulating factor (GM-CSF), a unifyin

196 Flt3) ligand-induced, but not in granulocyte macrophage-colony-stimulating factor (GM-CSF)-induced DC

197 DG172 strongly augmented granulocyte-macrophage-colony-stimulating factor (GM-CSF)-induced di

198 rleukin 10 [IL-10], IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF], IL-4, and

199 enes coding for proinflammatory (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophag

200 [SCF], Flt-3/Flk-2 ligand [FL], granulocyte/macrophage-colony stimulating factor [GM-CSF], interleuk

201 ations than controls (n = 42) of granulocyte-macrophage colony-stimulating factor [(GM-CSF) 16.2 fold

202 0), IL-13, TNF-alpha, IFN-gamma, granulocyte-macrophage colony-stimulating factor, granulocyte colony

203 IL-17A, IL-22, interferon-gamma, granulocyte macrophage colony-stimulating factor, IL-13).

204 ation increased the secretion of granulocyte macrophage-colony stimulating factor, IL-12, -13, and -1

205 k, whereas vasopressin decreased granulocyte-macrophage colony-stimulating factor in patients who had

206 When osteoclast precursors were induced by macrophage colony-stimulating factor in the presence of

207 uced LHPC proliferation, whereas granulocyte-macrophage-colony stimulating factor induced differentia

208 Activation of microglia with macrophage colony-stimulating factor induces trafficking

209 or activator of nuclear factor kappaB ligand/macrophage colony-stimulating factor induction of nuclea

210 n degranulation and secretion of granulocyte-macrophage colony-stimulating factor, interferon gamma,

211 ytokines and chemokines, such as granulocyte macrophage colony-stimulating factor, interferon-gamma,

212 ungs, constitutive expression of granulocyte-macrophage colony-stimulating factor, interleukin-18, in

213 interleukin-10, interleukin-17, granulocyte-macrophage colony-stimulating factor, interleukin-1beta,

214 is DC subset was stimulated with granulocyte-macrophage colony-stimulating factor, interleukin-4, CD4

215 s of various cytokines including granulocyte-macrophage colony-stimulating factor, interleukin-6 (IL-

216 High levels of serum cytokines (granulocyte macrophage colony-stimulating factor, interleukin-6, int

217 f the common beta subunit of the granulocyte-macrophage colony-stimulating factor/interleukin-3 recep

218 Granulocyte-macrophage colony-stimulating factor is a potent stimula

219 Granulocyte-macrophage colony-stimulating factor is a potential ther

220 ts increased cFms expression and response to macrophage colony-stimulating factor, leading to a cell-

221 Macrophage colony stimulating factor (M-CSF) was implica

222 omoting cytokines [interleukin (IL-6), VEGF, macrophage colony-stimulating factor (M-CSF) ] and chemo

223 rophages and macrophages differentiated with macrophage colony-stimulating factor (M-CSF) alone (term

224 d osteoclastogenesis medium with 20 ng/mL of macrophage colony-stimulating factor (M-CSF) and 50 ng/m

225 ic phenotypes of macrophages stimulated with macrophage colony-stimulating factor (M-CSF) and granulo

226 fibrosis stages have higher serum levels of macrophage colony-stimulating factor (M-CSF) and interle

227 The molecular interactions between macrophage colony-stimulating factor (M-CSF) and the tyr

228 or activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) as well as

229 Here, we investigated the role of macrophage colony-stimulating factor (M-CSF) in TAM diff

230 Macrophage colony-stimulating factor (M-CSF) is a hemato

231 nsforming growth factor-beta (TGF-beta), and macrophage colony-stimulating factor (M-CSF) levels.

232 the effects of stimulating macrophages with macrophage colony-stimulating factor (M-CSF) on muscle r

233 demonstrate that monocytes differentiated by macrophage colony-stimulating factor (M-CSF) or granuloc

234 Macrophage colony-stimulating factor (M-CSF) promotes mo

235 axonal spheroids (HDLS), which is caused by macrophage colony-stimulating factor (M-CSF) receptor mu

236 timulation of hematopoietic progenitors with macrophage colony-stimulating factor (M-CSF) resulted in

237 The efficacy of a preventive macrophage colony-stimulating factor (M-CSF) treatment w

238 or activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (m-CSF), critical o

239 ochastic cellular proliferation in situ in a macrophage colony-stimulating factor (M-Csf)- and granul

240 We generated macrophage colony-stimulating factor (M-CSF)-derived mon

241 e the delicate balance between apoptosis and macrophage colony-stimulating factor (M-CSF)-induced mye

242 ogenesis, beta-catenin is induced during the macrophage colony-stimulating factor (M-CSF)-mediated qu

243 stimulating factor (GM-CSF)-polarized M1 and macrophage colony-stimulating factor (M-CSF)-polarized M

244 Absence of TLN1 impairs macrophage colony-stimulating factor (M-CSF)-stimulated

245 (RANKL), either alone or in the presence of macrophage colony-stimulating factor (M-CSF).

246 gulation of macrophage glucose metabolism by macrophage colony-stimulating factor (M-CSF; inflammatio

247 tal structure of BARF1 in complex with human macrophage-colony stimulating factor (M-CSF), a hematopo

248 ignaling-dependent, CD103(+)CD11b(-) DCs and macrophage-colony stimulating factor (M-CSF)-dependent,

249 ast formation and functions are regulated by macrophage-colony-stimulating factor (M-CSF) and recepto

250 Granulocyte-macrophage colony stimulating factor may be beneficial f

251 e profiled 48 serum cytokines and identified macrophage colony-stimulating factor (MCSF) as one of th

252 ses of amphotericin B and another activator, macrophage colony-stimulating factor (MCSF), further ele

253 ively (interleukin-4 [IL-4]) or classically (macrophage colony-stimulating factor [MCSF]) activated M

254 crophage colony-stimulating factor [GM-CSF], macrophage colony-stimulating factor [MCSF], interleukin

255 determine whether treatment with granulocyte-macrophage colony stimulating factor might alter importa

256 nic effects of radiotherapy with granulocyte-macrophage colony-stimulating factor might result in abs

257 Interleukin-4, interleukin-8, granulocyte macrophage colony-stimulating factor, monocyte chemotact

258 B-cell depletion or granulocyte-macrophage colony-stimulating factor neutralization inhi

259 strated that, when cultured with granulocyte macrophage-colony-stimulating factor, neutrophils can gi

260 irradiated ID8 cells expressing granulocyte macrophage colony-stimulating factor or FLT3 ligand) and

261 t of CUS-exposed mice with either endotoxin, macrophage colony-stimulating factor or granulocyte-macr

262 n in vivo systemic inhibition of granulocyte-macrophage colony-stimulating factor or interferon-gamma

263 r (GM-CSF) plus blockade of the M2 cytokines macrophage colony-stimulating factor or MIF.

264 bo vs. 17% in patients receiving granulocyte-macrophage colony stimulating factor (p = .31) and organ

265 C motif) ligand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.001), thus c

266 s placebo vs. 15.7 +/- 11.9 days granulocyte-macrophage colony stimulating factor, p = .16) were not

267 s placebo vs. 10.8 +/- 10.5 days granulocyte-macrophage colony stimulating factor, p = .82).

268 of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor produced more TRAP(

269 combination of radiotherapy with granulocyte-macrophage colony-stimulating factor produced objective

270 nd 3-fold upregulated numbers of granulocyte-macrophage colony-stimulating factor-producing B cells w

271 Granulocyte macrophage colony-stimulating factor-producing IRA B cel

272 ers interferon-gamma, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subs

273 utation had reduced responses to granulocyte-macrophage colony-stimulating factor, providing an addit

274 unction of circulating leukocyte granulocyte-macrophage colony-stimulating factor receptor (CD116) me

275 /CD11b(high) cells and greater expression of macrophage colony-stimulating factor receptor (M-CSFR) i

276 ; P < 0.0001); and expression of granulocyte-macrophage colony-stimulating factor receptor beta subun

277 MacGreen reporter mice (mice expressing the macrophage colony-stimulating factor receptor GFP transg

278 ciency to increase interleukin 3/granulocyte-macrophage colony-stimulating factor receptor signaling

279 ction, and surface expression of granulocyte-macrophage colony-stimulating factor receptor; all three

280 itment to the Flt3 locus vs GM-CSF-alpha and macrophage-colony-stimulating factor receptor loci.

281 C production of the osteoclastogenic factors macrophage colony-stimulating factor, receptor activator

282 Granulocyte-macrophage colony-stimulating factor-receptor-alpha expr

283 Granulocyte-macrophage colony-stimulating factor-receptor-alpha was

284 on genes, such as macrophage and granulocyte macrophage colony-stimulating factor receptors (MCSFR an

285 ted and expression of CSF2RB and granulocyte-macrophage colony-stimulating factor-responsive cells we

286 l lamina propria leukocytes with granulocyte-macrophage colony-stimulating factor resulted in high le

287 te colony-stimulating factor and granulocyte-macrophage colony-stimulating factor resulted in the gen

288 ed in vitro to recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) (1 ng/mL

289 Using recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as a mod

290 GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreting allogenei

291 recently described population of granulocyte macrophage colony-stimulating factor-secreting cells of

292 d does not induce hyperactivated granulocyte macrophage colony-stimulating factor signaling or increa

293 tope, in a setting that includes granulocyte macrophage colony-stimulating factor-stimulated macropha

294 A isoform 121, bone morphogenetic protein 7, macrophage colony-stimulating factor, stromal cell-deriv

295 d the immunomodulatory adjuvants granulocyte-macrophage colony-stimulating factor, Toll-like receptor

296 In a randomized phase II trial, granulocyte-macrophage colony stimulating factor treatment did not i

297 rentiation induced by GM-CSF, did not affect macrophage-colony-stimulating factor-triggered different

298 The Csf1r locus encodes the receptor for macrophage colony-stimulating factor, which controls the

299 eosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor with first pulmonar

300 d progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor with myeloid cell d